{
    "organizations": [],
    "uuid": "779e02d504b209e0477826b25d058b7d659d53e7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mercks-keytruda-significantly-impr/brief-mercks-keytruda-significantly-improved-recurrence-free-survival-compared-to-placebo-as-adjuvant-therapy-idUSFWN1P30GG",
    "ord_in_thread": 0,
    "title": "BRIEF-Merck's Keytruda Significantly Improved Recurrence-Free Survival Compared To Placebo As Adjuvant Therapy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - Merck & Co Inc:\n* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED RECURRENCE-FREE SURVIVAL COMPARED TO PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH STAGE 3 RESECTED HIGH-RISK MELANOMA (EORTC1325/KEYNOTE-054)\n* MERCK & CO INC - PHASE 3 EORTC1325/KEYNOTE-054 TRIAL MET PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL\n* MERCK -SAFETY PROFILE OF KEYTRUDA IN TRIAL WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES INVOLVING PATIENTS WITH ADVANCED MELANOMA\n* MERCK & CO INC - IN ACCORDANCE WITH TRIAL PROTOCOL, STUDY WILL CONTINUE IN ORDER TO EVALUATE OTHER KEY ENDPOINTS, INCLUDING OVERALL SURVIVAL Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-08T19:55:00.000+02:00",
    "crawled": "2018-01-09T16:59:12.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "merck",
        "co",
        "inc",
        "merck",
        "pembrolizumab",
        "significantly",
        "improved",
        "survival",
        "compared",
        "placebo",
        "adjuvant",
        "therapy",
        "patient",
        "stage",
        "resected",
        "melanoma",
        "merck",
        "co",
        "inc",
        "phase",
        "trial",
        "met",
        "primary",
        "endpoint",
        "survival",
        "merck",
        "profile",
        "keytruda",
        "trial",
        "consistent",
        "observed",
        "previously",
        "reported",
        "study",
        "involving",
        "patient",
        "advanced",
        "melanoma",
        "merck",
        "co",
        "inc",
        "accordance",
        "trial",
        "protocol",
        "study",
        "continue",
        "order",
        "evaluate",
        "key",
        "endpoint",
        "including",
        "overall",
        "survival",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}